Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry

Jessica C.L. Notohardjo*, Malou C.P. Kuppen, Hans M. Westgeest, Reindert J.A. van Moorselaar, Niven Mehra, Jules L.L.M. Coenen, Inge M. van Oort, Aad I. de Vos, Walter L. Vervenne, Alphons C.M. van den Bergh, Katja K.H. Aben, Diederik M. Somford, Andries M. Bergman, Carin A. Uyl-de Groot, Winald R. Gerritsen, Alfons J.M. van den Eertwegh

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Third-line life-prolonging drugs (LPDs) might not be appropriate for all metastatic castration-resistant prostate cancer patients. We developed a prognostic model and identified a high-risk subgroup in which no meaningful benefit from third-line LPDs is derived in clinical practice.

Original languageEnglish
JournalEuropean Urology Focus
DOIs
Publication statusAccepted/In press - 1 Jan 2020

Cite this